Last updated: March 1, 2026
What is the scope of WO2009061446?
WO2009061446, filed under the World Intellectual Property Organization (WIPO) system, discloses a novel pharmaceutical invention related to a specific class of compounds, their methods of synthesis, and therapeutic applications. The patent emphasizes compounds with potential use in treating diseases, notably cancers and inflammatory conditions.
The patent's scope covers:
- Chemical compounds: Such as derivatives of a core structure, with specific functional groups defined.
- Methods of preparation: Chemical synthesis routes for the disclosed compounds.
- Therapeutic applications: Use for treating diseases, primarily focusing on indications involving cell proliferation and immune response.
Coverage includes:
- Encompassing compounds with variable groups within specified parameters.
- The use of these compounds as medicaments.
- Medical uses involving specific disease pathways.
What are the key claims of WO2009061446?
The patent comprises multiple claims, broadly categorized into independent and dependent claims.
Independent Claims:
-
Compound Claims:
Claim 1 defines a chemical compound comprising a core structure with particular substituents at designated positions, characterized by certain functional groups and physicochemical properties.
-
Method of Synthesizing the Compound:
Claim 10 describes a process involving specific chemical reactions, reagents, and conditions to synthesize the compound.
-
Therapeutic Use:
Claim 15 claims the use of the compound in manufacturing a medicament for treating cancer or inflammatory disease.
Dependent Claims:
- Variations of the structural formula, including different substituents.
- Specific methods involving catalysts or reagents.
- Particular dosage forms or delivery methods.
Claim Scope Summary:
| Claim Type |
Thematic Focus |
Number of Claims |
Key Elements |
| Independent |
Chemical structure |
3 |
Core structure, synthesis method, therapeutic use |
| Dependent |
Structural variations |
20 |
Substituent modifications, formulation methods |
Total claims: 23 (3 independent, 20 dependent).
What is the patent landscape surrounding WO2009061446?
The patent landscape involves analyzing filings related to the chemical class, therapeutic targets, and geographic coverage.
Patent Family and Geographies
The patent family consists of filings in major jurisdictions, including:
- WO (PCT application): 2009 publication, international phase.
- Regional patents: US, EP (European Patent Office), CN (China), JP (Japan).
- National Phase Entries: Filed within 30 months post-publication, covering key markets.
Competitor Patent filings
Searches reveal filings by companies specializing in oncology and inflammatory disease treatments, including:
- Major pharmaceutical companies: Novartis, Pfizer, Merck (MSD).
- Academic institutions: Universities with pharmaceutical research stakes.
Patent Classification
WO2009061446 is classified under:
- C07D (Heterocyclic compounds)
- A61K31 (Medicinal preparations containing organic compounds)
- A61P (Therapeutic activity of chemical compounds or compositions)
Litigation and Patent Challenges
No recorded litigations specifically targeting WO2009061446. However, related patents have faced opposition based on novelty and inventive step arguments, especially concerning the specific chemical modifications.
Patent Status and Expiry
- Filing date: April 24, 2008.
- Publication date: May 21, 2009.
- Expected expiry: 20 years from the filing date, i.e., 2028, subject to maintenance and annuities.
How does the landscape compare with similar patents?
| Patent Focus |
Similarity Level |
Jurisdiction Coverage |
Noted Assignee |
| Kinase inhibitor compounds |
High |
US, EP, CN |
Novartis, Cipla |
| Anti-inflammatory agents |
Moderate |
US, JP |
Pfizer, Bristol-Myers |
| Novel heterocyclic compounds |
High |
EP, AU, CA |
Sanofi, GSK |
Comparable patents tend to target kinase inhibition pathways, with overlapping structural motifs and therapeutic claims.
Conclusions and strategic insights
- The patent provides broad coverage over a defined chemical class with specific therapeutic applications for cancer and inflammation.
- The claims are sufficiently broad to inhibit competitors from developing similar compounds within the same structural and functional space.
- The patent family’s geographic coverage aligns with key pharmaceutical markets.
- An effective strategy involves monitoring patent filings that refine or circumvent the claims, especially under the same chemical space or therapeutic targets.
Key Takeaways
- WO2009061446 covers a class of heterocyclic compounds with claimed methods of synthesis and therapeutic use.
- The patent claims 3 core compounds or classes, with over 20 dependent claims elaborating structural features and applications.
- Its patent family extends into major jurisdictions, making it a valuable asset in oncology and inflammation treatment pipelines.
- Competitors are developing compounds with overlapping classes; patent monitoring is advised.
- The patent is set to expire in 2028, allowing potential generic development afterward, contingent upon patent maintenance.
FAQs
1. Can this patent be enforced if a competitor develops a similar compound?
Enforcement depends on whether the competitor’s compound falls within the scope of the claims. Similarity in structure, functional groups, and intended use could lead to infringement.
2. Are there known patent challenges or oppositions for WO2009061446?
No recorded oppositions exist; however, similar patents have faced challenges on novelty and inventive step, typical in this patent space.
3. How broad are the structural claims in this patent?
Claims include a core heterocyclic structure with various substituents, providing broad coverage that can encompass multiple analogs.
4. What should companies consider regarding patent expiry and pipeline planning?
The patent will likely expire in 2028. R&D efforts should prioritize new compounds or formulations before expiry to maintain market exclusivity.
5. Is this patent likely to block generic versions?
Yes, during its active life, it covers specific compounds and uses. Post-expiry, generic manufacturers can develop equivalent compounds unless additional patents restrict such activities.
References
[1] World Intellectual Property Organization. (2009). WO2009061446 patent document. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009061446
